Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Aged 18 years and over; - Cardiomyopathy defined by an ultrasound thickness of the left ventricle greater than or equal to13 mm if familial form, or greater than or equal to 15 mm if sporadic form; - Patients with a signed consent authorising the specific blood test for genetic sequencing to look for an abnormal TTR gene. ","clusion_E":"Significant AS (less than or equal to 1cm2); - Patients with a cardiomyopathy diagnosis (sarcomeric HCM, Fabry disease, etc.) or related already diagnosed.Patients included in the REMY registry (Hypertrophic Cardiomyopathy Registry) may also be included in the amyloid-STUDY. Inclusion criteria are very similar. Some additional data will need to be completed on the page corresponding to the registry."}